Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maju Mathews

Showing results (41-50 of 91) with videos related to

Pageof 10
Sort By:
Advances in Therapy|November 5, 2017
Paliperidone Palmitate Improves and Maintains Functioning in Asia-Pacific Patients with SchizophreniaHongyan Zhang, Ibrahim Turkoz, Jianmin Zhuo, et al.
Neuropsychiatric Disease and Treatment|March 19, 2020
Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority StudySrihari Gopal, Jagadish Gogate, Katalin Pungor, et al.
International Clinical Psychopharmacology|August 15, 2017
Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority studyAdam J Savitz, Haiyan Xu, Srihari Gopal, et al.
Expert Opinion on Pharmacotherapy|August 9, 2019
A post hoc analysis on hospitalization risk in Asian patients with schizophrenia switching to once-monthly paliperidone palmitate from oral antipsychoticsNan Li, Jian Min Zhuo, Ibrahim Turkoz, et al.
Journal of Clinical Psychopharmacology|November 6, 2019
Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month FormulationsAlberto Russu, Adam Savitz, Maju Mathews, et al.
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)|April 18, 2019
Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studiesAdam J Savitz, Haiyan Xu, Srihari Gopal, et al.
Journal of Affective Disorders|October 19, 2016
Long-term safety and tolerability of asenapine: A double-blind, uncontrolled, long-term extension trial in adults with an acute manic or mixed episode associated with bipolar I disorderTerence A Ketter, Suresh Durgam, Ronald Landbloom, et al.
The Journal of Clinical Psychiatry|December 4, 2014
Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trialHarry A Croft, Nunzio Pomara, Carl Gommoll, et al.
The Primary Care Companion for CNS Disorders|August 4, 2016
Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With VilazodoneArif Khan, Suresh Durgam, Xiongwen Tang, et al.
Patient Preference and Adherence|August 6, 2020
Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference QuestionnaireClifton Blackwood, Panna Sanga, Isaac Nuamah, et al.
Pageof 10

Showing results (41-50 of 91) with videos related to

Sort By:
Pageof 10
Advances in Therapy|November 5, 2017
Paliperidone Palmitate Improves and Maintains Functioning in Asia-Pacific Patients with SchizophreniaHongyan Zhang, Ibrahim Turkoz, Jianmin Zhuo, et al.
Neuropsychiatric Disease and Treatment|March 19, 2020
Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority StudySrihari Gopal, Jagadish Gogate, Katalin Pungor, et al.
International Clinical Psychopharmacology|August 15, 2017
Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority studyAdam J Savitz, Haiyan Xu, Srihari Gopal, et al.
Expert Opinion on Pharmacotherapy|August 9, 2019
A post hoc analysis on hospitalization risk in Asian patients with schizophrenia switching to once-monthly paliperidone palmitate from oral antipsychoticsNan Li, Jian Min Zhuo, Ibrahim Turkoz, et al.
Journal of Clinical Psychopharmacology|November 6, 2019
Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month FormulationsAlberto Russu, Adam Savitz, Maju Mathews, et al.
Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999)|April 18, 2019
Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studiesAdam J Savitz, Haiyan Xu, Srihari Gopal, et al.
Journal of Affective Disorders|October 19, 2016
Long-term safety and tolerability of asenapine: A double-blind, uncontrolled, long-term extension trial in adults with an acute manic or mixed episode associated with bipolar I disorderTerence A Ketter, Suresh Durgam, Ronald Landbloom, et al.
The Journal of Clinical Psychiatry|December 4, 2014
Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trialHarry A Croft, Nunzio Pomara, Carl Gommoll, et al.
The Primary Care Companion for CNS Disorders|August 4, 2016
Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With VilazodoneArif Khan, Suresh Durgam, Xiongwen Tang, et al.
Patient Preference and Adherence|August 6, 2020
Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference QuestionnaireClifton Blackwood, Panna Sanga, Isaac Nuamah, et al.
Pageof 10